elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Topotecan
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Topotecan
RIS
0.001
(Research Intensity Score)
Papers
81
Top papers
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2025 · 214 citations
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
2023 · 457 citations
BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality
2023 · 135 citations
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
2021 · 296 citations
Dual-Modulation ratiometric fluorescence strategy for cobalt and topotecan detection using Red-Emissive carbon dots
2024 · 43 citations
Newest papers
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial
2026 · 3 citations
Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science
2026 · 3 citations
Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan
2026
Solvent-controlled Rh-catalysed hydrodehalogenation and construction of phenanthridinone skeleton from a common precursor in one-step sequence and the antitumor activity of its derivatives
2026
Solvent-controlled Rh-catalysed hydrodehalogenation and construction of phenanthridinone skeleton from a common precursor in one-step sequence and the antitumor activity of its derivatives
2026
A sample from the 81 top papers behind Topotecan.
Create a free account to browse them all →
Topotecan's history
Research intensity over time
Explore Topotecan's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Topotecan's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link